title: Fluoxetine in children and adolescents with OCD: a placebo-controlled trial.
abstract: OBJECTIVE
  To examine the safety and efficacy of fluoxetine in child and adolescent obsessive-compulsive disorder (OCD).
  
  
  METHODS
  Between 1991 and 1998, 43 patients were randomly assigned to fluoxetine or placebo for 8 weeks. Dosing was fixed for the first 6 weeks (up to 60 mg/day) and then could be increased to 80 mg/day. Responders entered an 8-week maintenance phase. The primary outcome measures were the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) and the Clinical Global Impression-Improvement (CGI-I) scale. Analyses were done on the intent-to-treat sample.
  
  
  RESULTS
  Fluoxetine patients (n = 21) had significantly lower CY-BOCS scores than placebo patients (n = 22) after 16 (but not 8) weeks. Fluoxetine responders (n = 11) had significantly lower CY-BOCS scores than placebo responders (n = 7) after an additional 8 weeks of treatment. After 16 weeks, 57% of fluoxetine (versus 27% of placebo) patients were much or very much improved on the CGI-I scale (p <.05). No patient terminated the study because of adverse medication effects.
  
  
  CONCLUSIONS
  Fluoxetine was well tolerated and effective for the treatment of child and adolescent OCD, but fluoxetine's full effect took more than 8 weeks to develop.
authors.affiliation: New York State Psychiatric Institute, Department of Psychiatry, Columbia University, New York 10032, USA.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Liebowitz
authors.forename: Samuel M
authors.initials: SM
authors.lastname: Turner
authors.forename: John
authors.initials: J
authors.lastname: Piacentini
authors.forename: Deborah C
authors.initials: DC
authors.lastname: Beidel
authors.forename: Susan R
authors.initials: SR
authors.lastname: Clarvit
authors.forename: Sharon O
authors.initials: SO
authors.lastname: Davies
authors.forename: Flemming
authors.initials: F
authors.lastname: Graae
authors.forename: Margaret
authors.initials: M
authors.lastname: Jaffer
authors.forename: Shu-Hsing
authors.initials: SH
authors.lastname: Lin
authors.forename: Floyd R
authors.initials: FR
authors.lastname: Sallee
authors.forename: Andrew B
authors.initials: AB
authors.lastname: Schmidt
authors.forename: H Blair
authors.initials: HB
authors.lastname: Simpson
mesh_terms: D000293:Adolescent; D002648:Child; D004305:Dose-Response Relationship, Drug; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis / Q000188:drug therapy*; D010552:Personality Assessment; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors